Comparison of Anti-Ischemic Drug Therapy and Percutaneous Transluminal Angioplasty After Myocardial Infarction
Swiss Interventional Study on Silent Ischemia (SWISSI 2)
1 other identifier
interventional
N/A
1 country
1
Brief Summary
Silent ischemia has been shown to negatively affect prognosis in patients after myocardial infarction. However, long-term outcome data in totally asymptomatic patients is missing and it is unknown whether angioplasty in addition to secondary preventive measures is superior to antiischemic drug therapy in these patients. Therefore, the SWISSI 2 study was started 15 years ago with the aim of comparing the effects of angioplasty with medical therapy on long-term outcome in patients with recent myocardial infarction and silent ischemia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jun 1991
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 1991
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2006
CompletedFirst Submitted
Initial submission to the registry
October 10, 2006
CompletedFirst Posted
Study publicly available on registry
October 12, 2006
CompletedOctober 12, 2006
October 1, 2006
October 10, 2006
October 10, 2006
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Combination of cardiac death, non-fatal myocardial infarction, and symptom-driven revascularization
Secondary Outcomes (1)
Overall mortality; Cardiac death; Non-fatal myocardial infarction; Symptom-driven revascularization.
Interventions
Eligibility Criteria
You may qualify if:
- Recent myocardial infarction within last 3 months
- Documented silent myocardial ischemia (type I)
You may not qualify if:
- Symptomatic myocardial ischemia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Cardiology, Hospital Lucerne
Lucerne, Canton of Lucerne, 6000, Switzerland
Related Publications (2)
Schoenenberger AW, Jamshidi P, Kobza R, Zuber M, Stuck AE, Pfisterer M, Erne P. Progression of coronary artery disease during long-term follow-up of the Swiss Interventional Study on Silent Ischemia Type II (SWISSI II). Clin Cardiol. 2010 May;33(5):289-95. doi: 10.1002/clc.20775.
PMID: 20513067DERIVEDErne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, Dubach P, Resink TJ, Pfisterer M. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA. 2007 May 9;297(18):1985-91. doi: 10.1001/jama.297.18.1985.
PMID: 17488963DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Paul Erne, MD
Department of Cardiology, Hospital Lucerne
- PRINCIPAL INVESTIGATOR
Paul Erne, MD
Department of Cardiology, Hospital Lucerne
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
October 10, 2006
First Posted
October 12, 2006
Study Start
June 1, 1991
Study Completion
May 1, 2006
Last Updated
October 12, 2006
Record last verified: 2006-10